Pharma News

The key evaluation endpoint of this Phase II, single-arm study on the efficacy and safety of sravanti in EGFR-mutant and MET-overexpressing and/or MET-amplified locally advanced or metastatic NSCLC patients progressing.

In the weight-loss drug market, semaglutide was once seen as a rising star driving growth. However, a recent in-depth analysis has raised doubts about this growth trajectory.

Semaglutide, a novel weight-loss medication, has been the subject of much attention in the market.

Hillevax's market capitalization has declined to $1,000,000, primarily due to the company's disclosure that its bivalent norovirus vaccine (HIL-218) failed to meet the primary endpoint for preventing acute gastroenteritis.

In the 2023 fiscal year, HilleVax's investment in research and development (R&D) increased significantly to $106.7 million, up from $45.9 million in the previous year.

Cell and gene therapy (CGT) is an emerging treatment strategy that stands out for its potential "one-time treatment, permanent cure" capability, offering many patients the possibility of long-term relief from their medical conditions.

As the global healthcare industry experiences a period of robust growth, the frequency of mergers and acquisitions (M&A) among pharmaceutical companies has been steadily increasing.

According to Takeda's 2023 fiscal year business report, the company's annual total revenue reached 4,263.8 billion yen, an increase of 5.9% year-over-year.

According to the recent "2023 Annual Drug Review Report" published by China's National Medical Products Administration, China has achieved significant results in the field of drug development.

Spiber, a leading innovator in synthetic biology, has recently announced a supply chain partnership with three renowned Italian textile giants - Marzotto, RDGruppoFlorence, and FilaturaPapiFabio.

In the surging global spider silk protein market, Chinese innovative companies are investing in research and production at an unprecedented pace and scale.

In recent years, Aurisco Pharmaceutical has achieved remarkable success in its focus on formulation products.

In Aurisco Pharmaceutical's carefully planned and strategic roadmap, the peptide and oligonucleotide businesses have been assigned a crucial role, viewed as the key engines driving the company's future growth.

In the recent round of centralized procurement of insulin, the market dynamics have attracted widespread attention.

In the context of intensifying global competition in the insulin market, Ganlee Pharmaceutical, a leading Chinese diabetes drug development company, is actively expanding its innovative footprint in the GLP-1 receptor agonist (GLP-1RA) field.

On July 2nd, Samsung Biologics solemnly announced that the company has successfully reached a strategic partnership agreement worth 14.6 trillion KRW (approximately $10.6 billion) with an anonymous American pharmaceutical giant.

As a globally acclaimed medication, semaglutide has been making waves with its exceptional therapeutic effects.

Pfizer is set to welcome a new leader for its oncology business, who will take on the responsibility of helping the company achieve its ambitious goal of having 8 major impact oncology drugs by 2030.

AstraZeneca China implemented a significant organizational restructuring, dismantling and reorganizing its county-level oncology teams, and integrating them into the Lung Cancer Business Unit and the Urology, Gynecology and Women's Oncology Business Unit.

Rob Hoedt, Executive Vice President and President of Medtronic's global regions, revealed that he will be retiring from his distinguished career on June 28th, opting to start his retirement journey earlier than the company's mandatory retirement age of 65